Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAXBiotechnology
+$0.00 today
- Market cap
- $622.71M
- Beta
- -0.53
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$2.59
Volume 1.30M
Average 0.54M
BCAX Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Bicara Therapeutics Inc. Common StockNASDAQ: BCAX
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation grows, but more slowly than its trailing trend
Q1 FY2026 stock-based compensation of $5.86M rose 69.7% year over year, behind the +79.5% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 31.7% from the prior quarter. Over 3 fiscal years it compounded at +164.6% a year.
Context
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +69.7% toward the trailing-twelve-month pace of +79.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 15.01M USD
- Year-over-year change
- +102.9%
- 3-year CAGR
- +164.6%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 15.01M | +102.9% |
| FY2024 | 2024-12-31 | 7.4M | +289.5% |
| FY2023 | 2023-12-31 | 1.9M | +134.4% |
| FY2022 | 2022-12-31 | 810K | — |
Stock-Based Compensation vs competitors
How BCAX compares with its peers on the latest reported figures
- BCAX's LTM Mar 2026 stock-based compensation of $17.41M is the 2nd largest of the 6 companies compared; the peer median is $12.55M.
- Its year-over-year change of +79.5% is the 2nd highest of 6, against a peer median of +20.5%.
- Over three fiscal years its annual growth of +164.6% compares with a peer median of +10.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $34.28M | -12.0% | +8.8% | — | |
BCAXBicara Therapeutics Inc. Common Stock | LTM Mar 2026 | $17.41M | +79.5% | +164.6% | — |
| LTM Mar 2026 | $16.18M | +309.7% | +51.1% | 136.2% | |
| LTM Mar 2026 | $12.55M | -55.6% | -11.3% | 8.0% | |
| LTM Mar 2026 | $10.93M | +20.5% | +16.2% | — | |
| LTM Mar 2026 | $1.45M | +61.5% | +10.9% | — | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding BCAX) | $12.55M | +20.5% | +10.9% | 72.1% | |
Competitors are the stored peer set for BCAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (37.85M) | (51.99M) | (68M) | (137.95M) |
| Depreciation & Amortization | 10K | 19K | 56K | 406K |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 810K | 1.9M | 7.4M | 15.01M |
| Change in Working Capital | 4.95M | (9.62M) | (14.13M) | 14.81M |
| Accounts Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 2.64M | 0 |
| Other Working Capital | 4.95M | (9.62M) | (16.77M) | 14.81M |
| Other Non-Cash Items | 810K | 14.06M | (77K) | 895K |
| Operating Cash Flow | (32.08M) | (45.63M) | (74.75M) | (106.83M) |
| Capital Expenditures | (192K) | (586K) | (71K) | (280K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (318.17M) |
| Sales of Investments | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 62K | 0 |
| Investing Cash Flow | (192K) | (586K) | (9K) | (318.45M) |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 332.43M | 32.26M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 160K | 149K | 1.6M | 0 |
| Financing Cash Flow | 31.7M | 272.5M | 334.03M | 32.26M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | (573K) | 226.28M | 259.27M | (393.03M) |
| Free Cash Flow | (32.27M) | (46.21M) | (74.82M) | (107.11M) |
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
Intrinsic Alpha fair value
Locked
Current Price
$9.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.